Willow Biosciences Inc. (3D7.F)
| Previous close | 0.0655 |
| Open | 0.0630 |
| Bid | 0.0590 x N/A |
| Ask | 0.0800 x N/A |
| Day's range | 0.0630 - 0.0630 |
| 52-week range | 0.0395 - 0.0950 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 8.62M |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.00 |
PR NewswireWILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS
Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces a multi-product development and licensing partnership with Laurus Labs ("Laurus") (Bombay Stock Exchange Code: 540222; LAURUSLABS-IN: National Stock Exchange of India), a leading research-driven pharmaceutical and biotechnology company with a $3.9 billion market cap that serves global pharmac
PR NewswireWILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further progress in its commercial expansion.
Simply Wall St.Willow Biosciences Full Year 2023 Earnings: CA$0.10 loss per share (vs CA$0.12 loss in FY 2022)
Willow Biosciences ( TSE:WLLW ) Full Year 2023 Results Key Financial Results Revenue: CA$1.17m (up 43% from FY 2022...
